

# Influenza Vaccine Products for the 2012–2013 Influenza Season

Information about influenza vaccine products

Manufacturer	Trade Name	How Supplied	Mercury Content (µg Hg/0.5mL)	Age Group	Product Code <sup>1</sup>
CSL Biotherapies	Afluria (TIV) <sup>2</sup>	0.5 mL (single-dose syringe)	0	9 years & older <sup>3</sup>	90656
		5.0 mL (multi-dose vial)	24.5		90658 Q2035 (Medicare)
GlaxoSmithKline	Fluarix (TIV)	0.5 mL (single-dose syringe)	0	3 years & older	90656
ID Biomedical Corp of Quebec, a subsidiary of GlaxoSmithKline	FluLaval (TIV)	5.0 mL (multi-dose vial)	<25	18 years & older	90658 Q2036 (Medicare)
MedImmune	FluMist (LAIV) <sup>2</sup>	0.2 mL (single-use nasal spray)	0	2 through 49 years	90660
Novartis Vaccines	Fluvirin (TIV)	0.5 mL (single-dose syringe)	≤1	4 years & older	90656
		5.0 mL (multi-dose vial)	25		90658 Q2037 (Medicare)
sanofi pasteur	Agriflu (TIV)	0.5 mL (single-dose syringe)	0	18 years & older	90658 Q2034 (Medicare)
	Fluzone (TIV)	0.25 mL (single-dose syringe)	0	6 through 35 months	90655
		5.0 mL (multi-dose vial)	25	6 through 35 months	90657
		0.5 mL (single-dose syringe)	0	3 years & older	90656
		0.5 mL (single-dose vial)	0	3 years & older	90656
		5.0 mL (multi-dose vial)	25	3 years & older	90658 Q2038 (Medicare)
	Fluzone High-Dose (TIV)	0.5 mL (single-dose syringe)	0	65 years & older	90662
Fluzone Intradermal (TIV)	0.1 mL (single-dose microinjection system)	0	18 through 64 years	90654	

## FOOTNOTES

- Effective for claims with dates of service on or after 1/1/2011, CPT (Current Procedural Terminology) code 90658 is no longer payable for Medicare; rather, HCPCS (Healthcare Common Procedure Coding System) Q codes, as indicated above, should be submitted for Medicare payment purposes.
- TIV is the abbreviation for trivalent inactivated influenza vaccine (injectable); LAIV is the abbreviation for live attenuated influenza vaccine (nasal spray).
- On August 6, 2010, ACIP recommended that Afluria not be used in children younger than age 9 years. If no other age-appropriate TIV is available, Afluria may be considered for a child age 5 through 8 years at high risk for influenza complications, after risks and benefits have been discussed with the parent or guardian. Afluria should not be used in children younger than age 5 years. This recommendation continues for the 2012–2013 influenza season.